Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbohydrate response element-binding protein (ChREBP) is a basic helix-loop-helix leucine zipper (bHLH/LZ) transcription factor that acts as a "glucose sensor". It regulates genes involved in glycolysis and de novo lipogenesis by binding to carbohydrate response element (ChoRE) motifs in target gene promoters. Its activity is regulated by intracellular metabolites and post-translational modifications. ChREBP is highly expressed in the liver but also present in adipose tissue, intestine, kidney, and pancreatic β-cells. Dysregulation of ChREBP is implicated in metabolic diseases such as non-alcoholic fatty liver disease and type 2 diabetes.
Heterodimerizes with MLX, binds to ChoRE motifs in target gene promoters, and activates gene transcription in a glucose-dependent manner.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carbohydrate response element-binding protein (ChREBP).